Keros kicks off DMD drug trial and reports Q2 2026 results

Keros Therapeutics initiated a Phase 2 trial for rinvatercept in Duchenne muscular dystrophy and reported a Q2 net loss of $28.7 million, with cash expected to fund operations through mid-2028. The company reported a 48% decrease in operating costs due to restructuring.